Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessXeris Pharmaceuticals (XERS) Receives New Price Target from Piper Sandler

Xeris Pharmaceuticals (XERS) Receives New Price Target from Piper Sandler

Add to Favorite
Added to Favorite


On Friday, May 10, 2024, David Amsellem of Piper Sandler set a new price target for Xeris Pharmaceuticals (NASDAQ:XERS) at $3, as reported by StreetInsider. This new target suggests a significant potential upside of 62.43% from its trading price at the time, which was approximately $1.85. This adjustment in the price target reflects a positive outlook on the company’s financial future, despite its recent performance challenges.
Xeris Biopharma, the company behind XERS, reported a quarterly loss of $0.14 per share, which did not meet the expectations set by the Zacks Consensus Estimate of a $0.12 per share loss. This result indicates a slight deterioration in the company’s financial health compared to the previous year’s loss of $0.12 per share. The earnings surprise of -16.67% for this quarter suggests that the company’s losses were larger than what analysts had anticipated. This trend of not meeting earnings expectations has been consistent, as seen in the previous quarter, where the company also reported a larger loss than expected.
Despite these challenges, Xeris Biopharma reported revenues of $40.64 million for the quarter ending March 2024. Although this figure fell short of the Zacks Consensus Estimate by 2.21%, it represents a growth from the previous year’s revenues of $33.2 million. This growth in revenue has not been consistent enough to meet or exceed consensus revenue estimates regularly, having only done so twice over the last four quarters. This inconsistency highlights the difficulties Xeris Biopharma faces in achieving steady financial growth.
The company’s stock performance reflects these financial challenges. XERS is currently trading at $1.825, experiencing a decrease of approximately 2.93% for the day. The stock has fluctuated between a low of $1.82 and a high of $1.91 during the trading session, indicating volatility in its market value. Over the past year, XERS has seen a high of $3.26 and a low of $1.46, with a market capitalization of around $270.56 million. This volatility and the company’s current market position underscore the cautious optimism embedded in Piper Sandler’s new price target, suggesting that while there are challenges, there may also be potential for recovery and growth in Xeris Pharmaceuticals’ financial outlook.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Arch Capital Group’s Market Outlook and Financial Performance

Michael Zaremski from Capital One Financial set a price...

Jazz Pharmaceuticals’ Financial and Operational Highlights

Earnings per Share (EPS) of $3.40, missing the estimated...

Clarivate Plc (NYSE:CLVT) Q3 Earnings Overview

Clarivate Plc reported a Q3 EPS of -$0.09128, missing...

Clean Energy Fuels Corp. (NASDAQ: CLNE) Financial Performance Review

Clean Energy Fuels Corp. (NASDAQ:CLNE) reported a revenue of...